
    
      Primary Objective

      â€¢ To determine overall response rate (CR+PR) of brentuximab vedotin in CD30 low (<10%)
      relapsed or refractory T cell lymphoma (TCL)

      Secondary Objective(s)

        -  Complete remission (CR) rate

        -  Duration of response (DOR)

        -  Progression free survival (PFS)

        -  Overall survival (OS)

        -  Time to treatment failure (TTF)
    
  